ClinicalTrials.gg
CompletedNCT06541457Updated Sep 15, 2025

A Study on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-7249 Injection in Healthy Subjects

A Phase 1 interventional study of HRS-7249 injection and Placebo in Hyperlipidemia, sponsored by Fujian Shengdi Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-15.

Sponsored by Fujian Shengdi Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Hyperlipidemias by Jiangsu HengRui Medicine Co., Ltd. — 3 open to participants now, 5 under way, 1 of them phase 3. Hyperlipidemias · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
10th of 14
48 · median 78
Started
2024
with 1 other
Phase 1
8 of 14
none open now
Registered
5th of 14
by date

Among the 14 studies in Hyperlipidemias by Jiangsu HengRui Medicine Co., Ltd., this one is the 10th largest by enrollment, is one of 2 that started in 2024, is one of 8 in phase 1, and was the 5th registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

3 of the 14 studies in Hyperlipidemias by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Hyperlipidemias by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

It is a randomized, double-blind, single-dose, placebo-controlled phase I clinical trial. The study plans to conduct four to six dose groups of dose 1, dose 2, dose 3, dose4, dose5 (optional), and dose 6(optional). Eight subjects will be enrolled for each dose group, with six administered HRS-7249 injection and two administered placebo. A total of 32 to 48 healthy subjects are planned to be enrolled.

03

Conditions studied

  • Hyperlipidemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide a written ;
  2. Age ≥ 18 and ≤ 65 years old on the day of signing the informed consent ;
  3. 0.9 mmol/L≤TG≤5.6 mmol/L;
  4. Male or female;
  5. Male subjects weigh ≥ 50 kg and \< 90 kg , female subjects weigh ≥ 45kg and \< 90 kg, and is in the range of 19\~30 kg/m2 ;(including boundary values) Normal or abnormality such as vital signs, physical examination and laboratory examination have no clinical significance;
  6. Subjects must be willing to use a highly effective method of as deemed appropriate by the investigator throughout the study and for at least 6 months after the last study drug administration.

Exclusion criteria

Exclusion Criteria:

  1. Those who suffer from any disease that affects drug absorption, distribution, metabolism, and excretion, or can reduce compliance determined by investigators;
  2. Those who suffer from any clinical diseases such as as cardiovascular, liver, kidney, digestive tract, psychiatric, hematological, metabolic abnormalities;
  3. A history of drug allergies or atopic allergic diseases (asthma, urticaria, eczematous dermatitis);
  4. Those with a history of malignant diseases;
  5. Those with a history of involving clinical trials of any other drugs or medical devices within the previous 3 months of screening or planned to be conducted during the study period (excluding screening failures), or those who are still within 5 half-lives of the drugs before screening (whichever is longer);
  6. Those who have experienced severe trauma or surgery within the previous 6 months, or plan to undergo surgery during the trial period; Serious infected individuals within the previous 3 months of screening;
  7. Those who have used any drugs during the screening period or within 2 weeks before the baseline period; or those who are still in 5 half-lives of the drug at the time of screening (whichever is longer);
  8. Serum LDL-C ≥ 4.1mmol/L;
  9. count\<100 × 109/L;
  10. Creatinine≥ (ULN);
  11. (ALT), aspartate aminotransferase (AST), or gamma glutamyltransferase (GGT) ≥2×ULN, or total ≥1.5×ULN;
  12. During the screening period, antibodies (HIV-Ab), syphilis serological tests, virus surface antigen (HBs-Ag), or virus antibodies (HCV Ab) is positive;
  13. Creatine kinase (CK) ≥ 3 ×ULN;
  14. Thyroid stimulating hormone (TSH)\< limit of normal (LLN) or≥ 1.5 ×ULN;
  15. (eGFR)\<60 mL/min/1.73m2;
  16. Urine drug screening positive;
  17. Those with a history of blood donation within the previous three months, severe blood loss (blood loss ≥ 400 mL), or who have received a blood transfusion within four weeks;
  18. Those who have received the vaccine within the previous two weeks or plan to receive it during the trial process;
  19. Those who started new physical exercise or made significantly changed their previous exercise activities within the previous 4 weeks, or who were unable to maintain basic stability in exercise during the study period;
  20. Those who have made significant adjustments to their previous diet within the previous 4 weeks, or those whose diet cannot maintain basic stability during the study period;
  21. Those who smoke an average of 5 or more cigarettes per day within the previous 4 weeks;
  22. In the four weeks before screening, women's daily alcohol intake was more than 15 g, men's more than 25 g and more than twice a week, or the screening period and baseline period alcohol breath test (alcohol blood test can be replaced) was positive;
  23. Those with a history of drug use or abuse;
  24. Researchers, assistant researchers, research assistants, pharmacists, research coordinators, or other directly involved protocol implementers;
  25. The researchers believe that subjects with any unfavorable factors to participate in this experiment.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Treatment for intravenously: dose 1

    Drug: HRS-7249 injection · Drug: Placebo

  • Experimental
    Treatment for intravenously: dose 2

    Drug: HRS-7249 injection · Drug: Placebo

  • Experimental
    Treatment for intravenously: dose 3

    Drug: HRS-7249 injection · Drug: Placebo

  • Experimental
    Treatment for intravenously: dose 4

    Drug: HRS-7249 injection · Drug: Placebo

  • Experimental
    Treatment for intravenously: dose 5 (optional)

    Drug: HRS-7249 injection · Drug: Placebo

  • Experimental
    Treatment for intravenously: dose 6 (optional)

    Drug: HRS-7249 injection · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Safety and tolerability: Incidence of subjects with adverse events (AEs)

    Time frame: Baseline up to Day 169

Secondary outcomes

  1. Pharmacokinetics (PK) parameter: AUC0-t for HRS-7249

    AUC0-t: Area under the plasma concentration-time curve from time zero to the time of last quantifiable analyte concentration

    Time frame: Baseline up to 48 hours after dosing

  2. Pharmacokinetics (PK) parameter: AUC0-∞ for HRS-7249

    AUC0-∞: Area under the plasma concentration-time curve from time zero extrapolated to infinity

    Time frame: Baseline up to 48 hours after dosing

  3. Pharmacokinetics (PK) parameter: Cmax for HRS-7249

    Cmax: Maximum plasma concentration

    Time frame: Baseline up to 48 hours after dosing

  4. Pharmacokinetics (PK) parameter: Tmax for HRS-7249

    Tmax: Time to reach maximum plasma concentration

    Time frame: Baseline up to 48 hours after dosing

  5. Pharmacokinetics (PK) parameter: t1/2 for HRS-7249

    t1/2: Terminal half-life

    Time frame: Baseline up to 48 hours after dosing

  6. Pharmacokinetics (PK) parameter: CL/F of HRS-7249 for administration subcutaneously

    CL/F: Apparent clearance

    Time frame: Baseline up to 48 hours after dosing

  7. Pharmacokinetics (PK) parameter: V/F of HRS-7249 for administration subcutaneously

    V/F: Apparent volume of distribution

    Time frame: Baseline up to 48 hours after dosing

  8. Pharmacodynamics (PD): TG

    Time frame: Baseline up to Day 169

  9. Pharmacodynamics (PD): HDL-C

    Time frame: Baseline up to Day 169

  10. Pharmacodynamics (PD): LDL-C

    Time frame: Baseline up to Day 169

  11. Pharmacodynamics (PD): non-HDL-C

    Time frame: Baseline up to Day 169

  12. Pharmacodynamics (PD): VLDL-C

    Time frame: Baseline up to Day 169

  13. Pharmacodynamics (PD): TC

    Time frame: Baseline up to Day 169

  14. Pharmacodynamics (PD): Lp(a)

    Time frame: Baseline up to Day 169

  15. Pharmacodynamics (PD): ApoB

    Time frame: Baseline up to Day 169

  16. Pharmacodynamics (PD): ApoA1

    Time frame: Baseline up to Day 169

  17. Immunogenicity: Proportion of anti-drug antibodies (ADA) positive subjects

    Time frame: Baseline up to Day 169

07

Study locations

1 site
  • The Second Affiliated Hospital Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310009, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Jul 2025, 11 months.

Of 47 industry-sponsored phase 1 interventional studies under Hyperlipidemias, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 10. This study's 11 months is above that.

Counting every sponsor, half of 54 studies reached it within 3 months; a quarter within 1 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2024
First posted
Aug 7, 2024
StartActual
Aug 15, 2024
Primary completionActual
Jul 30, 2025
CompletionActual
Jul 30, 2025
Last update
Sep 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06541457
Responsible party
Sponsor
First posted
Aug 7, 2024
Start date
Aug 15, 2024
Primary completion
Jul 30, 2025
Completion
Jul 30, 2025
Last update
Sep 15, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-7249

Start the discussion